MASH is serious, but not hopeless. 

MDAS is metabolically dysfunctional steatohepatitis.

Definition: Fat buildup causes inflammation and liver cell destruction in progressive fatty liver disease. The buildup of fat in the liver, inflammation, and scarring cause the debilitating liver disease known as Metabolically Dysfunctional-Associated Steatohepatitis (MASH). Doctors formerly called it nonalcoholic steatohepatitis (NASH), and researchers link it to insulin resistance, type 2 diabetes, obesity, and high cholesterol. New Terminology: NASH became MASH to underline metabolic dysfunction. MASH is part of Metabolically Associated Steatotic Liver Disease (MASLD).

Symptoms

• MASH often goes undiagnosed until liver damage is severe. Signs may include:
• Fatigue
• Upper right abdominal pain
• Unexpected weight loss or muscular weakening
• Belly or leg swelling
• Cases of severe jaundice

Possible Risks

• More likely to develop MASH:
• Overweight or obesity
• Type-2 diabetes
• High triglycerides or cholesterol
• High blood pressure
• Insulin resistance
• Even non-obese people with metabolic disorders like high cholesterol or hypertension can develop MASH.

Complications

• Untreated MASH can cause the following:
• Scarring/fibrous
• Cirrhosis (permanent scarring)
• Liver failure
• Hepatocellular carcinoma
• Heart attack and stroke risk increase.

Outlook

• Early stages: Lifestyle modifications and treatment can reverse or stabilise MASH.
• Advanced stages: Treatment can delay progression but increase the chance of liver transplant, malignancy, or early death.
• MASH affects 1.5–6.5% of U.S. adults and is expected to climb 63% by 2030.

What distinguishes fatty liver disease from steatohepatitis?

• Steatosis/MASLD
• Definition: The liver stores fat >5% of its weight.
• Early, typically reversible.
• Usually silent; may produce weariness or slight discomfort.
• Hypertension, obesity, type 2 diabetes, high cholesterol, and metabolic syndrome are risk factors.
• Some develop inflammation (steatohepatitis), but most remain stable.
• Fatty liver can be reversed by diet, exercise, and weight loss.

Steatohepatitis

• Liver fat accumulation, inflammation, and cell damage.
• Stage: Deadlier than simple fatty liver.
• Fatigue, stomach pain, edema, and acute jaundice.
• Complications:
• Scarring/fibrous
• Cirrhosis (permanent scarring)
• Hepatocellular carcinoma

Liver failure

• Treatment: Lifestyle adjustments, Resmetirom (Rezdiffra®), GLP-1 agonists, and bariatric surgery in severe cases.
• Steatohepatitis is a “danger stage.” It indicates inflammation and injury, increasing the risk of cirrhosis, liver cancer, and transplant. the 

How dangerous is steatohepatitis?

• Why It Matters
• Steatohepatitis can lead to cirrhosis, liver failure, or malignancy, unlike ordinary fatty liver.
• Silent progression: Many patients don't notice symptoms until the condition is advanced, making detection difficult.
• The condition is linked to metabolic disorders like obesity, diabetes, and high cholesterol, which increase heart disease and stroke risks.

Spectrum of severity

• Fat liver (steatosis): Only fat buildup, often reversible.
• Fat + inflammation + cell damage = steatohepatitis.
• Fibrosis produces scarring.
• Cirrhosis: Liver function diminishes due to severe scarring.
• Final complications: Liver failure, malignancy, and transplant.

Outcomes

• Early stages: Weight loss, nutrition, and exercise can reduce or reverse steatohepatitis.
• Advanced stages: Life-threatening consequences are more likely.
• It's becoming a major liver transplant cause worldwide.

Cure for steatohepatitis?

Steatohepatitis cannot be “cured” quickly, although it can be reversed or controlled if discovered early.

What’s Possible

• Starting before extensive scarring:
• Losing weight, dieting, and exercising lowers liver fat and inflammation.
• Often, the liver can recover and function normally.

Middle stages (fibrosis):

• Partial damage repair is possible.
• Resmetirom (Rezdiffra) and GLP-1 agonists (semaglutide, liraglutide, and tirzepatide) can reduce or reverse the development of.

Cirrhosis: Advanced stages

• Permanent scarring.
• Treatment objectives include liver transplantation, slowing damage, and managing complications.
• Diagnostic steatohepatitis due to metabolic dysfunction
• Blood testing, MRI, and liver biopsy diagnose metabolically dysfunction-associated steatohepatitis (MASH). Doctors look for liver inflammation and scarring in obese, diabetic, and high-cholesterol patients because it often develops silently.

Diagnostics of MASH

1. Medical history/physical exam

• Doctors check obesity, type 2 diabetes, excessive cholesterol, and high blood pressure.
• You may be asked about symptoms such as exhaustion, stomach pain, weight loss, oedema, or jaundice.

2. Blood tests

• ALT, AST, GGT: Elevated enzymes indicate liver damage.
• General health and organ function: CBC, BMP.
• Lipid panel: Triglycerides, cholesterol.
• Controlling blood sugar.
• Assess scarring risk with fibrosis scores (FIB-4, NAFLD activity score).

3. Imaging Exams

• Ultrasound detects fatty alterations (“bright liver”).
• CT or MRI: Detail imaging.
• Transient elastography (FibroScan®) measures liver scarring.
• MRE: Advanced fibrosis imaging by magnetic resonance elastography.
• MRE-PDFF measures liver fat.

4. Gold Standard Liver Biopsy

• Tiny tissue samples are examined under a microscope.
• Verifies obesity, inflammation, and scarring.
• This test is used for inconclusive non-invasive diagnostics or for suspected advanced disease.

Diagnostic Tools' Key Differences

• The test kind, what it detects, its accuracy, and its invasiveness.
• Moderate non-invasive blood testing for enzyme levels and metabolic risk.
• Ultrasound: Moderate fatty changes, non-invasive.
• FibroScan: Liver stiffness (fibrosis) High Non-invasive
• MRI/MRE: Fat + Fibrosis Very high Non-invasive
• Biopsy: Fat, inflammation, scarring. The most invasive

Why Diagnosis Matters

• With early detection, medication and lifestyle changes can lessen or even reverse illness.
• Delayed diagnosis increases the risk of cirrhosis, liver cancer, and transplant.
• Research shows that about 75% of MASH patients go undiagnosed, highlighting the importance of screening for metabolic disorders in people who are at risk.

MASH treatment

Metabolically-dysfunction-associated steatohepatitis (MASH) is treated with lifestyle modifications and recently approved medications such as Resmetirom (FDA-approved in 2024) and experimental GLP-1 agonists. Reducing liver fat, inflammation, and fibrosis while controlling metabolic risks like diabetes and obesity is the aim.

Primary Methods of Treatment

1. Modification of lifestyle (Foundation of Care)

• Significant weight loss (≥10%) can reduce inflammation and fibrosis.
• Low-carb or Mediterranean diets reduce liver fat.
• Weekly moderate exercise of 150–300 minutes.
• Steer clear of alcohol: It's essential for liver health.

2. Medicinal Interventions

• Rezdiffra®, or Resmetirom:
• This medication is the first FDA-approved drug for MASH with F2–F3 fibrosis.
• A thyroid hormone receptor-β agonist that reduces scarring and fat in the liver.
• GLP-1 receptor agonists include tirzepatide, liraglutide, and semaglutide.
• Improve metabolism, inflammation, and liver fat.
• Cardiovascular risk, the leading killer of MASH patients, should be reduced.

New medicines in trials:

• Multi-hormone agonists Survodutide and Retatrutide reduce liver fat significantly.
• Efruxifermin and pegozafermin target fibrosis and fat metabolism.
• Also, selonsertib and simtuzumab are fibrosis-targeted therapies, but their results have been inconsistent.

3. Surgery Options

• Patients with severe obesity (BMI ≥40, or ≥35 with comorbidities) may undergo bariatric surgery.
• It has been proven to lower liver fat, inflammation, and fibrosis.

Comparison of Treatments: Approach, Benefits, and Limitations

• Lifestyle adjustments can reverse early MASH and enhance health. Poor long-term sustainability
• Resmetirom is FDA-approved for fat and fibrosis reduction. Only F2–F3 fibrosis long-term data are evolving.
• GLP-1 agonists reduce weight, fat, inflammation, CV riskGI side effects, and cost
• Trials show strong fibrosis improvement with FGF21 mimics. Not commonly accessible.
• Bariatric surgery results in continuous weight decrease and fibrosis regression. Limited to eligible patients

Risks and Factors

• Cardiovascular disease kills most MASH patients, so treatment must target liver and heart health.
• While biomarkers evolve, non-invasive monitoring (FibroScan, MRI elastography) is replacing biopsy for progress tracking.
• Future standards may be a combination treatment of metabolic and liver-directed medications.

Medications:

• Rezdiffra®: FDA-approved for MASH with fibrosis stages 2–3.
• Semaglutide, liraglutide, and tirzepatide lower liver fat and inflammation.
• Vitamin E and pioglitazone are being studied.
• Obese people with advanced liver disease undergo bariatric surgery.

Conclusion

Progressive liver disease, Metabolically Associated Steatohepatitis (MASH), results from liver fat buildup, causing inflammation and cell injury.

It can result in cirrhosis, fibrosis, liver cancer, and liver failure in addition to simple fatty liver disease.

Though serious, MASH is not hopeless. Many individuals can stop or reverse disease progression with early diagnosis, lifestyle changes, and new medicines.